Replies to post #5800 on Halozyme Therapeutics Inc (HALO)

[maumar]

I guess a few things stood out:

1. The overall upbeat and bullish tone;
2. They project revenue growth between 18% and 26% with SC Darzalex expected to be approved in July and SC Perjeta/Herceptin probably not until 2021. If SC Darzalex gets approved earlier, revenue growth may be even higher.
3. They project earnings of $0.60 to $0.75 for 2020 even though my understanding is they won't be done with their cost cutting until Q4. This makes me think earnings could go up significantly in 2021 when revenue growth should explode with both SC Darzalex and, hopefully, SC Perjeta/Herceptin approved in early 2021.
4. "At least 3 new phase 3" clinical trial initiations. This increases the likelihood they will have a couple of new products approved in 2022 and get to perhaps $500M in royalties by 2025.